Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 37, Issue 3, 2012, Pages 211-216

  Xia, Zongling ^a   Wang, Mingli ^a   Zou, Sulan ^a   Chen, Rong ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

1,4 Dihydropyridine calcium channel antagonists; CytochromeP450 3A4; Inhibition constant; Quantitative structure activity relationship

Indexed keywords

1,4 DIHYDROPYRIDINE DERIVATIVE; AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; CYTOCHROME P450 3A4; FELODIPINE; LACIDIPINE; LERCANIDIPINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NITRENDIPINE;

ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER MICROSOME; MALE; MOLECULAR WEIGHT; PARTIAL LEAST SQUARES REGRESSION; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DIHYDROPYRIDINES; HUMANS; MICROSOMES, LIVER; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871334913     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0076-3     Document Type: Article

References (30)

1. Chen H (2006) Hepatic injury after using levoamlodipine besylate in combination with lovastatin and acipimox. Advers Drug React J 8(02):145
2. Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA (1999a) Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J Pharmacol Exp Ther 290(1):429-438
3. Ekins S, Bravi G, Wikel JH, Wrighton SA (1999b) Threedimensional- quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 291(1):424-433
4. Fayer JL, Petullo DM, Ring BJ, Wrighton SA, Ruterbories KJ (2001) A novel testosterone 6 beta-hydroxylase activity assay for the study of CYP3A-mediated metabolism, inhibition, and induction in vitro. J Pharmacol Toxicol Method 46(2):117-123
5. Guengerich FP, Bocker RH (1988) Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines. J Biol Chem 263(17): 8168-8175
6. Guengerich FP, Brian WR, Iwasaki M, Sari MA, Baarnhielm C, Berntsson P (1991) Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 34(6):1838-1844
7. Gibson GG, Skett P (eds) (1994) Introduction drug metabolism, 2nd edn. Blackie Academic & Professional, London
8. Hemmateenejad B, Akhond M, Miri R, Shamsipur M (2003) Genetic algorithm applied to the selection of factors in principal component-artificial neural networks: application to QSAR study of calcium channel antagonist activity of 1,4-dihydropyridines (nifedipine analogous). J Chem Inf Comput Sci 43(4): 1328-1334
9. Hemmateenejad B, Miri R, Akhond M, Shamsipur M (2002) Quantitative structure-activity relationship study of recently synthesized 1,4-dihydropyridine calcium channel antagonists. Application of the Hansch analysis method. Arch Pharm (Weinheim) 335(10):472-480
10. Hosseini M, Miri R, Amini M, Mirkhani H, Hemmateenejad B, Ghodsi S, Alipour E, Shafiee A (2007) Synthesis, QSAR and calcium channel antagonist activity of new 1,4-dihydropyridine derivatives containing 1-methyl-4, 5-dichloroimidazolyl substituents. Arch Pharm (Weinheim) 340(10):549-556
11. Iori F, da Fonseca R, Ramos MJ, Menziani MC (2005) Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorg Med Chem 13(14):4366-4374
12. Kakkar T, Boxenbaum H, Mayersohn M (1999) Estimation of Ki in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug Metab Dispos 27(6):756-762
13. Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T (2000) Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol 55(11-12):843-852
14. Kriegl JM, Eriksson L, Arnhold T, Beck B, Johansson E, Fox T (2005) Multivariate modeling of cytochrome P450 3A4 inhibition. Eur J Pharm Sci 24(5):451-463
15. Lewis DF (2000) Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 144(1-3):197-203
16. Lewis DF (2004) Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes. Toxicol In Vitro 18(1):89-97
17. Liang Z, Yang K, Chen B (2004) Cholesterol in U937 foam cells assayed in liquid chromatographic-mass spectrometry. Chin J Mod Med 14(20):51-53 ? 6
18. Liu L, Wang W, Yao C (2010) China's high blood pressure control guidelines (2009 grassroots version). Chin J Hypertens 18(01):11-30
19. McCalmont WF, Patterson JR, Lindenmuth MA, Heady TN, Haverstick DM, Gray LS, Macdonald TL (2005) Investigation into the structure-activity relationship of novel concentration dependent, dual action T-type calcium channel agonists/antagonists. Bioorg Med Chem 13(11):3821-3839
20. Meng Q, Liu X, Wang G (2004) Metabolic interaction of Cinildipine with some co-administrated drugs in human liver microsomes. J Chin Pharm Univ 35(06):4
21. Muntwyler J, Follath F (2001) Calcium channel blockers in treatment of hypertension. Prog Cardiovasc Dis 44(3):207-216
22. Nakamura K, Ariyoshi N, Iwatsubo T, Fukunaga Y, Higuchi S, Itoh K, Shimada N, Nagashima K, Yokoi T, Yamamoto K, Horiuchi R, Kamataki T (2005) Inhibitory effects of nicardipine to cytochrome P450 (CYP) in human liver microsomes. Biol Pharm Bull 28(5):882-885
23. Neuvonen PJ, Suhonen R (1995) Itraconazole interacts with felodipine. J Am Acad Dermatol 33(1):134-135
24. Niwa T, Shiraga T, Hashimoto T, Kagayama A (2004) Effect of nilvadipine, a dihydropyridine calcium antagonist, on cytochrome P450 activities in human hepatic microsomes. Biol Pharm Bull 27(3):415-417
25. Siller-Matula JM, Lang I, Christ G, Jilma B (2008) Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 52(19):1557-1563
26. Staessen JA, Thijs L, Celis H, Gasowski J, Wang JG, Fagard RH (2001) Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients - evidence from the Systolic Hypertension in Europe Trial. S Afr Med J 91(12):1060-1068
27. StresserDM, Blanchard AP, Turner SD, Erve JC,DandeneauAA,Miller VP, Crespi CL (2000) Substrate-dependent modulation ofCYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab Dispos 28(12):1440-1448
28. Tang J, Amin Usmani K, Hodgson E, Rose RL (2004) In vitro metabolism of fipronil by human and rat cytochrome P450 and its interactions with testosterone and diazepam. Chem Biol Interact 147(3):319-329
29. Triggle DJ (2007) Calcium channel antagonists: clinical uses - past, present and future. Biochem Pharmacol 74(1):1-9
30. Yoon YJ, Kim KB, Kim H, Seo KA, Kim HS, Cha IJ, Kim EY, Liu KH, Shin JG (2007) Characterization of benidipine and its enantiomers' metabolism by human liver cytochrome P450 enzymes. Drug Metab Dispos 35(9):1518-1524